Finally, we did not have tumours from patients to perform PD-L1 immunohistochemistry (IHC); however, given that IHC for PD-L1 has not been consistent as a prognostic factor for response to PD-1/PD-L1 inhibitors,52,53 we chose to focus on tumour genomics as a more robust and reproducible analysis that can have many clinical implications for management of mUC. This evidence concerns the gene CD274 and neoplasm.